{"id":"NCT03047395","sponsor":"AbbVie","briefTitle":"A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )","officialTitle":"A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-27","primaryCompletion":"2023-11-29","completion":"2023-11-29","firstPosted":"2017-02-09","resultsPosted":"2024-12-11","lastUpdate":"2024-12-11"},"enrollment":2170,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"risankizumab","otherNames":["ABBV-066","Skyrizi","BI 655066"]}],"arms":[{"label":"Risankizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Number of Participants With Serious Adverse Events and Non-Serious Adverse Events","timeFrame":"Median follow-up time of 1905 days","effectByArm":[{"arm":"Risankizumab 150 mg","deltaMin":435,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":233,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Finland","France","Germany","Japan","Mexico","Poland","Portugal","South Korea","Spain","Sweden","Taiwan"]},"refs":{"pmids":["40728772","39358667","39073712","34157132"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":435,"n":2170},"commonTop":["NASOPHARYNGITIS","COVID-19","UPPER RESPIRATORY TRACT INFECTION","HYPERTENSION","ARTHRALGIA"]}}